Effectiveness of Anakinra for Tocilizumab-refractory Severe COVID-19: A Single-centre Retrospective Comparative Study

Objectives: A subgroup of patients with SARS-CoV-2 infection was thought to have developed cytokine release syndrome and were treated with tocilizumab; however, a significant percentage of patients evolved. This study aimed to determine the usefulness of anakinra as a rescue treatment for patients with tocilizumab-refractory COVID-19 disease.

Methods: A prospective cohort of patients with COVID-19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) with selected controls in a historical cohort of patients treated with tocilizumab. Cases and controls were matched by age, comorbidities, pulse oximetry oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) ratio at baseline, and time elapsed since the initiation of treatment with tocilizumab. The primary outcome was the improvement in clinical status measured by a 6-point ordinal scale, from baseline to day 21.

Results: The study included 20 cases and 20 controls (mean age 65.3 ± 12.8 years, 65% males). No differences were found in the clinical improvement rates at 7, 14 and 21 days of follow-up. The in-hospital mortality rate for patients receiving anakinra was 55% vs. 45% in the control group (P = 0.527).

Conclusions: Treatment with anakinra was not useful in improving the prognosis of patients with tocilizumab-refractory severe COVID-19.

Citing Articles

From Cytokine Storm to Cytokine Breeze: Did Lessons Learned from Immunopathogenesis Improve Immunomodulatory Treatment of Moderate-to-Severe COVID-19?.

Rondovic G, Djordjevic D, Udovicic I, Stanojevic I, Zeba S, Abazovic T Biomedicines. 2022; 10(10).

PMID: 36289881 PMC: 9599155. DOI: 10.3390/biomedicines10102620.

Current evidence on the use of anakinra in COVID-19.

Khani E, Shahrabi M, Rezaei H, Pourkarim F, Afsharirad H, Solduzian M Int Immunopharmacol. 2022; 111:109075.

PMID: 35905562 PMC: 9296834. DOI: 10.1016/j.intimp.2022.109075.

Anakinra treatment efficacy in reduction of inflammatory biomarkers in COVID-19 patients: A meta-analysis.

Naveed Z, Sarwar M, Ali Z, Saeed D, Choudhry K, Sarfraz A J Clin Lab Anal. 2022; 36(6):e24434.

PMID: 35435272 PMC: 9110982. DOI: 10.1002/jcla.24434.

Predictors of poor outcome in tocilizumab treated patients with Sars-CoV-2 related severe respiratory failure: A multicentre real world study.

Masotti L, Landini G, Panigada G, Grifoni E, Tarquini R, Cei F Int Immunopharmacol. 2022; 107:108709.

PMID: 35334359 PMC: 8938681. DOI: 10.1016/j.intimp.2022.108709.

COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response.

Gur I, Giladi A, Isenberg Y, Neuberger A, Stern A Acta Haematol. 2022; 145(3):297-309.

PMID: 35235928 PMC: 9254311. DOI: 10.1159/000523872.

References

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

Salvarani C, Dolci G, Massari M, Merlo D, Cavuto S, Savoldi L . Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2020; 181(1):24-31. PMC: 7577199. DOI: 10.1001/jamainternmed.2020.6615. View

Divithotawela C, Garrett P, Westall G, Bhaskar B, Tol M, Chambers D . Successful treatment of cytomegalovirus associated hemophagocytic lymphohistiocytosis with the interleukin 1 inhibitor - anakinra. Respirol Case Rep. 2016; 4(1):4-6. PMC: 4722096. DOI: 10.1002/rcr2.137. View

Aouba A, Baldolli A, Geffray L, Verdon R, Bergot E, Martin-Silva N . Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series. Ann Rheum Dis. 2020; 79(10):1381-1382. DOI: 10.1136/annrheumdis-2020-217706. View

Innes A, Cook L, Marks S, Bataillard E, Crossette-Thambiah C, Sivasubramaniam G . Ruxolitinib for tocilizumab-refractory severe COVID-19 infection. Br J Haematol. 2020; 190(4):e198-e200. PMC: 7361819. DOI: 10.1111/bjh.16979. View

Villegas C, Poza M, Talayero P, Caro Teller J, Zafra D, Garcia C . IL-1R blockade is not effective in patients with hematological malignancies and severe SARS-CoV-2 infection. Ann Hematol. 2020; 99(12):2953-2956. PMC: 7314614. DOI: 10.1007/s00277-020-04160-w. View

Grom A, Horne A, De Benedetti F . Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol. 2016; 12(5):259-68. PMC: 5851441. DOI: 10.1038/nrrheum.2015.179. View

Figuero-Perez L, Olivares-Hernandez A, Escala-Cornejo R, Teran-Brage E, Lopez-Gutierrez A, Cruz-Hernandez J . Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab. Reumatol Clin (Engl Ed). 2021; 17(10):559-561. PMC: 7561306. DOI: 10.1016/j.reumae.2020.06.008. View

Stone J, Frigault M, Serling-Boyd N, Fernandes A, Harvey L, Foulkes A . Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020; 383(24):2333-2344. PMC: 7646626. DOI: 10.1056/NEJMoa2028836. View

10.

Mehta P, Cron R, Hartwell J, Manson J, Tattersall R . Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020; 2(6):e358-e367. PMC: 7198216. DOI: 10.1016/S2665-9913(20)30096-5. View

11.

Xu X, Han M, Li T, Sun W, Wang D, Fu B . Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020; 117(20):10970-10975. PMC: 7245089. DOI: 10.1073/pnas.2005615117. View

12.

Hermine O, Mariette X, Tharaux P, Resche-Rigon M, Porcher R, Ravaud P . Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2020; 181(1):32-40. PMC: 7577198. DOI: 10.1001/jamainternmed.2020.6820. View

13.

Pontali E, Volpi S, Antonucci G, Castellaneta M, Buzzi D, Tricerri F . Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease. J Allergy Clin Immunol. 2020; 146(1):213-215. PMC: 7211718. DOI: 10.1016/j.jaci.2020.05.002. View

14.

Giamarellos-Bourboulis E, Netea M, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N . Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020; 27(6):992-1000.e3. PMC: 7172841. DOI: 10.1016/j.chom.2020.04.009. View

15.

Cavalli G, Luca G, Campochiaro C, Della-Torre E, Ripa M, Canetti D . Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. Lancet Rheumatol. 2020; 2(6):e325-e331. PMC: 7252085. DOI: 10.1016/S2665-9913(20)30127-2. View

16.

. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respir Med. 2021; 9(3):295-304. PMC: 7825875. DOI: 10.1016/S2213-2600(20)30556-7. View

17.

Zangrillo A, Beretta L, Scandroglio A, Monti G, Fominskiy E, Colombo S . Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy. Crit Care Resusc. 2020; 22(3):200-211. PMC: 10692521. View

18.

Rice T, Wheeler A, Bernard G, Hayden D, Schoenfeld D, Ware L . Comparison of the SpO2/FIO2 ratio and the PaO2/FIO2 ratio in patients with acute lung injury or ARDS. Chest. 2007; 132(2):410-7. DOI: 10.1378/chest.07-0617. View

19.

Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F . Rapid and sustained remission of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol. 2010; 17(1):23-7. DOI: 10.1097/RHU.0b013e318205092d. View

20.

Balkhair A, Al-Zakwani I, Al Busaidi M, Al-Khirbash A, Al Mubaihsi S, BaTaher H . Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int J Infect Dis. 2020; 103:288-296. PMC: 7670920. DOI: 10.1016/j.ijid.2020.11.149. View